A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis.

Arthrodermataceae/drug effects administration allylamines/terbinafine antifungal agents/administration dosage/adverse effects/pharmacology drug compounding humans onychomycosis oral

Journal

Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827

Informations de publication

Date de publication:
04 Sep 2019
Historique:
received: 21 08 2019
revised: 01 09 2019
accepted: 03 09 2019
entrez: 7 9 2019
pubmed: 7 9 2019
medline: 7 9 2019
Statut: epublish

Résumé

Terbinafine has proved to treat numerous fungal infections, including onychomycosis, successfully. Due to its liver metabolization and dependency on the cytochrome P450 enzyme complex, undesirable drug interaction are highly probable. Additionally to drug interactions, the treatment is long, rising the chances of the appearance of side effects and abandonment. Pharmacokinetic data suggest that terbinafine maintains a fungicidal effect within the nail up to 30 weeks after its last administration, which has aroused the possibility of a pulse therapy to reduce the side effects while treating onychomycosis. This study's goal was to evaluate the effectiveness of three different oral terbinafine regimens in treating onychomycosis due to dermatophytes. Sixty-three patients with onychomycosis were sorted by convenience in three different groups. Patients from group 1 received the conventional terbinafine dose (250 mg per day for 3 months). Group 2 received a monthly week-long pulse-therapy dose (500 mg per day for 7 days a month, for 4 months) and group 3 received a 500 mg/day dose for 7 days every 3 months, totaling four treatments. There were no statistical differences regarding the effectiveness or side effects between the groups. Conclusion: A quarterly terbinafine pulse regimen can be a possible alternative for treating onychomycosis caused by dermatophytes.

Identifiants

pubmed: 31487828
pii: jof5030082
doi: 10.3390/jof5030082
pmc: PMC6787629
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Skinmed. 2020 Jan 01;18(1):18-22
pubmed: 32167451
Dermatol Ther. 2007 Jan-Feb;20(1):31-46
pubmed: 17403258
J Cutan Med Surg. 2018 May/Jun;22(3):318-322
pubmed: 29191054
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):387-398
pubmed: 29633864
J Fungi (Basel). 2019 Feb 22;5(1):
pubmed: 30813287
Exp Ther Med. 2018 Jan;15(1):785-788
pubmed: 29434682
Skin Appendage Disord. 2015 Sep;1(2):74-81
pubmed: 27170937
An Bras Dermatol. 2009 Sep-Oct;84(5):550-2
pubmed: 20098864
Pharmacoeconomics. 2001;19(4):401-10
pubmed: 11383756
Ned Tijdschr Geneeskd. 1995 Jul 1;139(26):1350-1
pubmed: 7617054
Mycopathologia. 2017 Feb;182(1-2):127-141
pubmed: 27502503
An Bras Dermatol. 2013 Nov-Dec;88(6):937-44
pubmed: 24474103
Gastroenterology. 2017 Apr;152(5):1078-1089
pubmed: 28043905
J Am Acad Dermatol. 2004 Feb;50(2):229-34
pubmed: 14726877
Br J Dermatol. 2007 Jul;157(1):149-57
pubmed: 17553051
J Cutan Med Surg. 2017 Nov/Dec;21(6):525-539
pubmed: 28639462
J Drugs Dermatol. 2018 Mar 1;17(3):253-262
pubmed: 29537443
Skin Appendage Disord. 2016 Sep;2(1-2):22-25
pubmed: 27843918
Clin Podiatr Med Surg. 2016 Jul;33(3):305-18
pubmed: 27215153
J Eur Acad Dermatol Venereol. 2009 Mar;23(3):256-62
pubmed: 19438818
J Am Acad Dermatol. 2019 Jul;81(1):276-278
pubmed: 30690048
Arch Dermatol. 2004 Jun;140(6):691-5
pubmed: 15210459
Clin Exp Dermatol. 1989 Mar;14(2):124-7
pubmed: 2689015
An Bras Dermatol. 2010 Sep-Oct;85(5):657-67
pubmed: 21152790
Br J Dermatol. 2020 Feb;182(2):287-299
pubmed: 31120134
J Am Acad Dermatol. 2019 Apr;80(4):853-867
pubmed: 29959962
J Am Acad Dermatol. 2011 Dec;65(6):1219-27
pubmed: 21501889
Comput Methods Programs Biomed. 2013 Oct;112(1):135-45
pubmed: 23871682
Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):262-6
pubmed: 16394436
Clin Exp Dermatol. 1989 Mar;14(2):110-3
pubmed: 2689012
Am J Clin Dermatol. 2019 Feb;20(1):123-133
pubmed: 30456537
J Am Acad Dermatol. 2005 Oct;53(4):578-84
pubmed: 16198776
Clin Dermatol. 2013 Sep-Oct;31(5):544-54
pubmed: 24079583
Rev Iberoam Micol. 2005 Mar;22(1):34-8
pubmed: 15813681
Clin Exp Dermatol. 1995 Sep;20(5):377-83
pubmed: 8593713
Br J Dermatol. 2012 Feb;166(2):389-98
pubmed: 21967490
Actas Dermosifiliogr. 2012 Jan;103(1):59-62
pubmed: 22456594
J Mycol Med. 2014 Dec;24(4):247-60
pubmed: 25458361
J Am Acad Dermatol. 2001 Jun;44(6):925-31
pubmed: 11369902
J Am Acad Dermatol. 2019 May;80(5):e105-e107
pubmed: 30447319
Skinmed. 2012 Jul-Aug;10(4):213-7
pubmed: 23008938
JAMA. 2018 Jan 23;319(4):397-398
pubmed: 29362778
Dermatol Ther. 2018 Jul;31(4):e12617
pubmed: 29786933
J Am Acad Dermatol. 2018 Mar;78(3):613-614
pubmed: 28947281
Pharmacoeconomics. 2002;20(5):319-24
pubmed: 11994041
Semin Cutan Med Surg. 2013 Jun;32(2 Suppl 1):S2-4
pubmed: 24156160
Clin Dermatol. 2018 Mar - Apr;36(2):159-166
pubmed: 29566920
J Am Acad Dermatol. 1998 May;38(5 Pt 3):S42-7
pubmed: 9594936
J Am Acad Dermatol. 2019 Apr;80(4):835-851
pubmed: 29959961
F1000Res. 2019 Jun 25;8:
pubmed: 31297182
Mycoses. 2009 Jan;52(1):72-6
pubmed: 18444971
G Ital Dermatol Venereol. 2019 Feb;154(1):50-55
pubmed: 29683287
J Fungi (Basel). 2018 Jul 24;4(3):
pubmed: 30042327
Mycopathologia. 2017 Feb;182(1-2):67-76
pubmed: 27502504
J Am Acad Dermatol. 1990 Oct;23(4 Pt 2):776-8
pubmed: 2229521
J Fungi (Basel). 2015 Mar 27;1(1):30-43
pubmed: 29376897
Pediatr Dermatol. 2018 Sep;35(5):552-559
pubmed: 29943838
Int J Dermatol. 2019 Oct;58(10):1118-1129
pubmed: 30585300
An Bras Dermatol. 2013 May-Jun;88(3):476-9
pubmed: 23793213
J Am Acad Dermatol. 2002 Oct;47(4):467-84; quiz 485-8
pubmed: 12271287
Skinmed. 2014 Jul-Aug;12(4):217-23
pubmed: 25335350

Auteurs

Anarosa B Sprenger (AB)

Santa Casa de Curitiba Hospital, Clinic of Diseases and Surgery of the Nail Apparatus, Department of Dermatology, Praça Rui Barbosa, 694, 80.010-030 Curitiba, Brazil. ana@anarosasprenger.com.br.

Katia Sheylla Malta Purim (KSM)

Hospital de Clínicas de Curitiba-Universidade Federal do Paraná (UFPR), Clinic of Dermatology, Rua General Carneiro, 181, 80.060-900 Curitiba, Brazil.

Flávia Sprenger (F)

Univerdidade Federal do Paraná (UFPR), Rua General Carneiro, 181, 80.060-900 Curitiba, Brazil.

Flávio Queiroz-Telles (F)

Hospital de Clínicas de Curitiba-Paraná Federal University (UFPR), Department of Public Health, Rua General Carneiro, 181, 80.060-900 Curitiba, Brazil.

Classifications MeSH